53462-88-7

Basic information

• Product Name: 3-formyl-1H-Indole-4-carboxylic acid methyl ester
• Synonyms: 1H-indole-4-carboxylic acid, 3-formyl-, methyl ester;3-Formyl-1H-indole-4-carboxylic acid methyl ester;Methyl 3-formyl-1H-indole-4-carboxylate;3-Formylindole-4-carboxylic acid methyl ester;4-(Methoxycarbonyl)-1H-indole-3-carboxaldehyde, 3-Formyl-4-(methoxycarbonyl)-1H-indole
• CAS NO: 53462-88-7
• Molecular Formula: C₁₁H₉NO₃
• Molecular Weight: 203.19
• Mol File: 53462-88-7.mol
• Article Data: 15

Chemical Properties

• Melting Point: 134-135 °C(Solv: benzene (71-43-2))
• Boiling Point: 404.415 °C at 760 mmHg
• Flash Point: 198.383 °C
• Appearance: /
• Density: 1.342 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.677
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.30±0.30(Predicted)
• CAS DataBase Reference: 3-formyl-1H-Indole-4-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-formyl-1H-Indole-4-carboxylic acid methyl ester(53462-88-7)
• EPA Substance Registry System: 3-formyl-1H-Indole-4-carboxylic acid methyl ester(53462-88-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 53462-88-7(Hazardous Substances Data)

Usage

General Description

3-formyl-1H-Indole-4-carboxylic acid methyl ester is a chemical compound with the molecular formula C12H11NO3. It is a methyl ester derivative of 3-formyl-1H-indole-4-carboxylic acid, and it belongs to the class of organic compounds known as indole carboxylic acids and derivatives. 3-formyl-1H-Indole-4-carboxylic acid methyl ester is commonly used in the pharmaceutical industry for the synthesis of various drugs and pharmaceutical compounds. It also has potential applications in organic synthesis and medicinal chemistry. However, it is important to handle this chemical with care as it may have hazardous properties and should be used in accordance with proper safety precautions.

InChI:InChI=1/C11H9NO3/c1-15-11(14)8-3-2-4-9-10(8)7(6-13)5-12-9/h2-6,12H,1H3

Upstream product

• 39830-66-5 methyl 1H-indole-4-carboxylate 
• 107-06-2 1,2-dichloro-ethane 
• 93-61-8 N-methyl-N-phenylformamide 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 100-61-8 N-methylaniline 
• 12591-02-5 phosphoryl oxychloride on N,N-dimethylformamide 
• 68-12-2 N,N-dimethyl-formamide 
• 67-56-1 methanol 
• 141692-10-6 (3-formylindol-4-yl)thallium (III) bistrifluoroacetate 

Downstream Products

• 53269-34-4 1,3,4,5-tetrahydro-pyrrolo[4,3,2-de]isoquinoline 
• 53462-75-2 3,4-dihydro-1H-pyrrolo[4,3,2-de]isoquinolin-5-one 
• 1059128-98-1 4-ethyl-1-(phenylsulfonyl)-1,3,4,5-tetrahydropyrrolo[4,3,2-de]isoquinoline trifluoroacetate 
• 1059129-07-5 1-[(2-chlorophenyl)sulfonyl]-4-ethyl-1,3,4,5-tetrahydropyrrolo[4,3,2-de]isoquinoline 
• 1059131-08-6 1-(phenylsulfonyl)-3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5(1H)-one 
• 1059128-87-8 4-methyl-1-(phenylsulfonyl)-1,3,4,5-tetrahydropyrrolo[4,3,2-de]isoquinoline 
• 1059128-86-7 1-(phenylsulfonyl)-1,3,4,5-tetrahydropyrrolo[4,3,2-de]isoquinoline 
• 1428129-84-3 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-formyl-1H-indole-4-carboxylate 
• 1428130-08-8 (E)-methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(3-ethoxy-3-oxoprop-1-en-1-yl)-1H-indole-4-carboxylate 
• 1428127-90-5 sodium 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(2-hydroxyethyl)-1H-indole-4-carboxylate 
• 1428129-94-5 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3,4-dihydrooxepino[5,4,3-cd]indol-6(1H)-one 
• 1428129-92-3 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(2-oxoethyl)-1H-indole-4-carboxylate 
• 1428129-90-1 methyl 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(2-methoxyvinyl)-1H-indole-4-carboxylate 
• 1428127-77-8 sodium 1-(5-chloro-2-((4-chloro-2-fluorobenzyl)oxy)benzyl)-3-(hydroxymethyl)-1H-indole-4-carboxylate 

Relevant articles and documents

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabet

5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE

Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling

We discovered a novel molecular framework 4 containing a heterobiaryl pyrazolopyridine moiety as a selective FLT3 kinase inhibitor from phenotype-based viability profiling. Compound 4g showed outstanding selectivity in cellular cytotoxicity against MV-4-11 leukemic cells via the induction of apoptosis. The hypothesis-driven deconvolution elucidated that compound 4g selectively blocked the phosphorylation of FLT3 and its downstream effectors, such as ERK and STAT5, only in MV-4-11 cells. The inhibitory effect of 4g on in vitro enzyme function and FLT3 phosphorylation in cells proved that FLT3 kinase is a direct molecular target of 4g. Finally, the kinase activity profiling of 4g verified its excellent selectivity toward FLT3 over 40 representative kinases, including the receptor tyrosine kinase (RTK) family. The Royal Society of Chemistry 2013.